1. Search Result
Search Result
Results for "

phosphoglycerate

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

6

Recombinant Proteins

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P2822

    PGK

    Endogenous Metabolite Infection Endocrinology Cancer
    Phosphoglycerate kinase, yeast (PGK), namely phosphoglycerate kinase, is a glycolytic enzyme commonly used in biochemical research. Phosphoglycerate kinase can catalyze the reversible transfer of phosphate groups from 1,3-bisphosphoglycerate (1,3-BPG) to ADP to generate 3-phosphoglycerate (3-PG) and ATP. At the same time, it can also participate in gluconeogenesis, catalyzing the opposite reaction to produce 1,3BPGA and ADP. Phosphoglycerate kinase is involved in energy metabolism, interaction with nucleic acid, tumor progression, cell death and virus replication and other related processes .
    <em>Phosphoglycerate</em> kinase, yeast
  • HY-148570

    Phosphoglycerate Dehydrogenase (PHGDH) Cancer
    PHGDH-IN-3 is an orally active phosphoglycerate dehydrogenase (PHGDH) inhibitor. PHGDH-IN-3 inhibits PHGDH with an IC50 value of 2.8 μM. PHGDH-IN-3 can be used for the research of cancer .
    PHGDH-IN-3
  • HY-134205A
    CBR-470-1
    1 Publications Verification

    Keap1-Nrf2 Neurological Disease Metabolic Disease
    CBR-470-1 is an inhibitor of the glycolytic enzyme phosphoglycerate kinase 1 (PGK1). CBR-470-1 is also a non-covalent Nrf2 activator. CBR-470-1 protects SH-SY5Y neuronal cells against MPP +-induced cytotoxicity through activation of the Keap1-Nrf2 cascade .
    CBR-470-1
  • HY-101966
    NCT-503
    10+ Cited Publications

    Phosphoglycerate Dehydrogenase (PHGDH) Cancer
    NCT-503 is a phosphoglycerate dehydrogenase (PHGDH) inhibitor with an IC50 of 2.5 µM.
    NCT-503
  • HY-101143

    Phosphatase Cancer
    PGMI-004A is a potent phosphoglycerate mutase 1 (PGAM1) inhibitor with an IC50 of 13.1 μM.
    PGMI-004A
  • HY-160252

    Phosphoglycerate Dehydrogenase (PHGDH) Cancer
    PHGDH-IN-4 is a phosphoglycerate dehydrogenase (PHGDH) inhibitor. PHGDH-IN-4 can be used for the research of cancer .
    PHGDH-IN-4
  • HY-128681
    PGAM1-IN-1
    1 Publications Verification

    Phosphatase Cancer
    PGAM1-IN-1 is a phosphoglycerate mutase 1 (PGAM1) inhibitor with an IC50 of 6.4 μM .
    PGAM1-IN-1
  • HY-128682

    Phosphatase Cancer
    PGAM1-IN-2 is a phosphoglycerate mutase 1 (PGAM1) inhibitor with an IC50 of 2.1 μM .
    PGAM1-IN-2
  • HY-123269

    Phosphoglycerate Dehydrogenase (PHGDH) Cancer
    PKUMDL-WQ-2101 is a non-NAD +-competing allosteric phosphoglycerate dehydrogenase (PHGDH) inhibitor with an IC50 of 34.8 μM. PKUMDL-WQ-2101 exhibits antitumor activity .
    PKUMDL-WQ-2101
  • HY-117240
    NCT-502
    5 Publications Verification

    Phosphoglycerate Dehydrogenase (PHGDH) Cancer
    NCT-502 is a human phosphoglycerate dehydrogenase (PHGDH) inhibitor, cytotoxic to PHGDH-dependent cancer cells, and reduces glucose-derived serine production, with an IC50 of 3.7 μM against PHGDH .
    NCT-502
  • HY-138877A

    Phosphatase Cancer
    Phosphoglycolic acid (lithium) is a competitive inhibitor of phosphoglycerate mutase (PGAM)-B, an enzyme of the glycolytic pathway. Phosphoglycolic acid increases basal and fMLF-induced levels of G6P in intact neutrophils. Phosphoglycolic acid thereby increases upstream intermediates in neutrophils, thereby amplifying the respiratory oxidative burst .
    Phosphoglycolic acid lithium
  • HY-126254
    BI-4924
    1 Publications Verification

    Phosphoglycerate Dehydrogenase (PHGDH) Cancer
    BI-4924 is a lipophilic, highly plasma protein bound selective phosphoglycerate dehydrogenase (PHGDH) inhibitor (IC50=3 nM) with excellent microsomal, as well as hepatocytic stability. Intracellular trapping of BI-4924 disrupts serine biosynthesis with an IC50 of 2200 nM at 72 h .
    BI-4924
  • HY-100012
    CBR-5884
    Maximum Cited Publications
    16 Publications Verification

    Phosphoglycerate Dehydrogenase (PHGDH) Cancer
    CBR-5884 is an active, selective inhibitor of phosphoglycerate dehydrogenase (PHGDH) with an IC50 of 33 μM. CBR-5884 inhibits de novo serine synthesis in cancer cells and is selectively toxic to cancer cell lines with high serine biosynthetic activity. CBR-5884 selectively inhibits the proliferation of melanoma and breast cancer lines that have a high propensity for serine synthesis .
    CBR-5884
  • HY-148510

    Phosphatase Cancer
    HKB99 is an allosteric inhibitor of phosphoglycerate mutase 1 (PGAM1). HKB99 inhibits the formation of invasive pseudopodia and increases the level of PAI-2 in vitro. HKB99 increases the oxidative stress, activates JNK/c-Jun and suppresses AKT and ERK. HKB99 can be used for the research of non-small-cell lung cancer (NSCLC) .
    HKB99
  • HY-15154
    NG 52
    4 Publications Verification

    Compound 52

    CDK Cancer
    NG 52 is a potent, cell-permeable, selective, ATP-compatible and orally active Cdc28p and Pho85p kinase inhibitor with IC50s of 7 μM and 2 μM, respectively. NG 52 also inhibits the activity of phosphoglycerate kinase 1 (PGK1) with an IC50 of 2.5 μM. NG 52 is inactive against yeast kinases Kin28p, Srb10, and Cak1p .
    NG 52

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: